TY - GEN
T1 - The Finnish boron neutron capture therapy (BNCT) project
AU - Auterinen, Iiro
PY - 1999
Y1 - 1999
N2 - Boron neutron capture therapy (BNCT) is a new, binary
radiotherapy, which is being developed especially for
severe brain tumours, incurable by the present means (for
an overview see articles in [1]). A suitable 10B
containing carrier compound is injected into the blood
circulation and taken up selectively by the cancer cells.
When these cells are subjected to a thermal neutron
field, the 10B atoms capture the neutrons and undergo
fission reaction. The energy thereby released is killing
the cancerous cell.
The Finnish BNCT research and development project [2,3]
is in the situation where all the basic conditions exist
to start clinical trials. An epithermal neutron
irradiation facility has been constructed at the Finnish
research reactor (FiR 1) operated by VTT in Otaniemi.
This article is an overview over the developments within
the Finnish BNCT project.
A research project to carry out clinical application of
BNCT was established in Finland in the early 1990's. It
was motivated both by the need to create new uses for FiR
1 and by the ideas to start research and production of
new boron carriers for BNCT in Finland. Soon also other
medical, medical physics and chemistry disciplines joined
the project [2,4,5]. Now the project involves scientists
from different departments of University of Helsinki
(HU), Helsinki University Central Hospital (HUCH),
Technical Research Centre of Finland (VTT), Finnish
Radiation and Nuclear Safety Authority (STUK) and of the
Helsinki University of Technology (HUT) and other Finnish
universities. The aim of this project has been to start
BNC-treatment of malignant brain tumours in Finland by
the end of the century.
AB - Boron neutron capture therapy (BNCT) is a new, binary
radiotherapy, which is being developed especially for
severe brain tumours, incurable by the present means (for
an overview see articles in [1]). A suitable 10B
containing carrier compound is injected into the blood
circulation and taken up selectively by the cancer cells.
When these cells are subjected to a thermal neutron
field, the 10B atoms capture the neutrons and undergo
fission reaction. The energy thereby released is killing
the cancerous cell.
The Finnish BNCT research and development project [2,3]
is in the situation where all the basic conditions exist
to start clinical trials. An epithermal neutron
irradiation facility has been constructed at the Finnish
research reactor (FiR 1) operated by VTT in Otaniemi.
This article is an overview over the developments within
the Finnish BNCT project.
A research project to carry out clinical application of
BNCT was established in Finland in the early 1990's. It
was motivated both by the need to create new uses for FiR
1 and by the ideas to start research and production of
new boron carriers for BNCT in Finland. Soon also other
medical, medical physics and chemistry disciplines joined
the project [2,4,5]. Now the project involves scientists
from different departments of University of Helsinki
(HU), Helsinki University Central Hospital (HUCH),
Technical Research Centre of Finland (VTT), Finnish
Radiation and Nuclear Safety Authority (STUK) and of the
Helsinki University of Technology (HUT) and other Finnish
universities. The aim of this project has been to start
BNC-treatment of malignant brain tumours in Finland by
the end of the century.
M3 - Conference article in proceedings
T3 - VTT Symposium
SP - 121
EP - 131
BT - 15th European TRIGA Conference
PB - VTT Technical Research Centre of Finland
CY - Espoo
T2 - 15th European TRIGA Conference
Y2 - 15 June 1998 through 17 June 1998
ER -